Global Antacids market size was worth $ 5.9 billion in 2018 and is forecasted to reach $ 7.6 billion by 2026, at a CAGR of 3.2% during the forecast period. Antacids are the over the counter medications used in neutralizing the stomach acid. They mainly work by reducing or preventing the secretion of stomach acids. They are mostly used in treating acid reflux, heartburn, indigestion. Growing prevalence of gastroesophageal reflux diseases and peptic ulcers is one of the primary drivers of the market, creating lucrative opportunities’ for the pharmaceutical companies to manufacture different drugs to meet the demand.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
Global Antacids market growth is driven by increasing prevalence of gastroesophageal reflux diseases, rising prevalence of heartburn, and increasing awareness about GERD and increasing side-effects related to non-steroidal anti-inflammatory drugs.
Increasing prevalence of GERD is one of the dominating factor propelling the global antacids market. For instance, according to a review article published in the International Foundation for Gastrointestinal Disorders in 2014, the prevalence estimates of GERD since 1995, in North America were around 18% to 28%, Europe had 9% to 26%, East Asia had 3% to 8%, Australia had about 12% and 9% to 33% in the Middle East, and 23% in South America. It is also suggested that there was an increase in GERD prevalence since 1995, mainly in North America and East Asia.
Rising prevalence of heartburn is expected to boost the market over the period of forecast. According to the American college of gastroenterology, more than 60 million Americans will experience heartburn at least once a month and more than 15 million Americans experience heartburn symptoms every day.
Increasing awareness about GERD is expected to boost the market. For instance, the International Foundation for Gastrointestinal Disorders has provided the information and support regarding GERDin the 19th Annual GERD Awareness Week, which was in November 2018. Also, it helps in educating individuals related to GERD and supports research regarding treatments and cures for GI disorders.
However, alternative treatment for antacids and increased side-effects related to antacids are hampering the market. For instance, alternative treatments which are likely to restrict the market for antacids include acupuncture, melatonin, hypnotherapy, herbal remedies, baking soda and lifestyle changes. Also, side effects related to antacids include dose-dependent rebound hyperacidity, milk-alkali syndrome, aluminium intoxication, osteomalacia, and hypophosphatemia are restraining the market growth.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/4532928-global-antacids-market-2019-2026
Global Antibacterial drugs market, By Type:
• Proton Pump Inhibitors
• H2 Antagonists
• Acid Neutralizers.
Proton pump inhibitors segment is expected to grow at a significant rate over the period of forecast. This is owing to Prescription PPI’s, easy availability of OTC PPI’s. Due to the acid-suppressing effects, they are approved for several short term indications like GERD, erosive esophagitis and duodenal and gastric ulcers. Long term indications include NSAID’s associated gastric ulcers, hypersecretory conditions, and maintenance of healing erosive esophagitis. For instance, the currently available PPI’s include omeprazole (Prilosec), lansoprazole (Prevacid), pantoprazole (Protonix), rabeprazole (Aciphex), esomeprazole (Nexium), dexlansoprazole (Dexilant) and Omeprazole with sodium bicarbonate (Zegerid, Zegerid OTC). A clinical trial related to PPI’s is expected to drive the market. For instance, according to Pulmonary Fibrosis News on January 25, 2019, a large, multi-centre clinical trial testing the proton pump inhibitor omeprazole was done as a therapy for cough in idiopathic pulmonary fibrosis (IPF) patients. It seems to be achievable and justified, according to the results of a single-centre pilot trial.
Global Antibacterial drugs market, By Formulation:
Tablet segment is expected to grow at a significant rate over the period of forecast. This is owing to the accurate dosage and secure storage of tablets when compared to other conventional formulations. Also, the presence of chewable tablets in the market with various flavours leading to improved patient adherence is expected to drive the market. For instance, Merck’s Pepcid Complete for heartburn associated with acid indigestion and sour stomach, Aciphex (rabeprazole sodium) of Elan Pharmaceuticals for treating symptomatic GERD and Protonix (pantoprazole sodium) Delayed-Release Tablets of Wyeth for treating Short-term treatment of erosive esophagitis associated GERD are some of the antacid tablets prevailing in the market.
Liquids segment is expected to grow at a high rate over the period of forecast. This is owing to the added advantages like a faster release, palatable taste. This is giving lucrative opportunities’ for the key players to manufacture liquid antacids. For instance, Pfizer’s Gelusil plus and Pepticaine, Gaviscon liquid OTC of GlaxoSmithKline, Maalox of Sanofi, Mylanta OTC of McNeil Consumer Healthcare are some of the popular liquid antacids in the market.
Global Antibacterial drugs market, By End-use:
• Hospital Pharmacies
• Retail Pharmacies
Retail pharmacies segment is expected to hold a significant market share over the period of forecast. This is owing to the easy availability and accessibility of a large number of otc drugs present in the retail pharmacies.
North America is dominating the global Antacids market in 2018 and estimated to hold the largest market size over the forecast period (2019-2026). This is owing to the rising prevalence of GERD, increasing the incidence of heartburn, increased awareness of GERD among the consumers.
Rising incidence of GERD is the dominating factor propelling the global antacids market. For instance, in 2017, CDC has reported that the number of visits in emergency departments with digestive system disorders was around 32.3 million. According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2010, 4.7 million hospitalizations and 1,653 deaths occurred due to GERD. Based on the Healthcare Cost and Utilization Project (HCUP), in 2005, there were around 3.14 million cases of GERD.Based on the National Institute of health ambulatory care visits due to GERD was 8.9 million in 2009.
Rising prevalence of heartburn is expected to boost the market over the period of forecast. According to the American college of gastroenterology, more than 60 million Americans will experience heartburn at least once a month and more than 15 million Americans experience heartburn symptoms every day. According to the researchers from the University of Michigan, acid reflux and heartburn affected more than 20% of the U.S. population in 2017.
However, over the forecast period (2019-2026), the Asia-Pacific is expected to dominate the Global Antacids market. This is owing to increased use of antacids for treating GERD and increased awareness of antacids among consumers. For instance, in August 2018,the latest reading of the Index of Industrial Production (IIP) has reported that the most significant contributor to the industrial growth in India was Digestive enzymes and antacids which include PPI drugs. Also, the presence of key players like GlaxoSmithKline, Pfizer etc. is expected to accelerate the market. For instance,Pfizer’s GEP (Global Established Products) division in India launched antacid Gelusil liquid in a ready-to-drink form in 2016. Abbott’s has launched Digene gel in India for relieving peptic ulcer, hyperacidity and heartburn.
Global Antacids Market Competitive Landscape
Some of the key players in the Global Antacids market are Pfizer, GlaxoSmithKline, Abbott India Private Ltd, Merck, AstraZeneca PLC, Bayer AG, Takeda pharmaceuticals, Sun pharmaceuticals, Sanofi, Dr Reddy’s Laboratories etc.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the Antacids market globally. For instance,
In 2016, Takeda Pharmaceutical’s has launched a proton pump inhibitor, Dexilant (Dexlansoprazole), for the treatment of GERD.
On May 31, 2017, Pfizer Limited (India) had agreed with AstraZeneca, to acquire the latter’s brand Neksium in India for a value of Rs 75 crore.
On September 2018, Abbott started “NoSecondOpinion campaign” for Digene, with the aim that people should prefer doctor’s recommendation to unsolicited advice.
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)